Lu AF87908 / Lundbeck - LARVOL DELTA

Passive tau-based immunotherapy for tauopathies. (PubMed, Handb Clin Neurol) - "At present, 12 anti-tau antibodies have entered clinical trials, and 7 of them are still in clinical testing for primary tauopathies and AD (semorinemab, bepranemab, E2814, JNJ-63733657, Lu AF87908, PNT00, and APNmAb005). Two other anti-tau monoclonal antibodies have been discontinued for the treatment of primary tauopathies, i.e., gosuranemab and tilavonemab. Further evidence will come from ongoing Phase I/II trials on passive immunotherapeutics for treating primary and secondary tauopathies."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Frontotemporal Lobar Degeneration • Movement Disorders • Progressive Supranuclear Palsy

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease (clinicaltrials.gov) - P1 | N=86 | Completed | Sponsor: H. Lundbeck A/S | Active, not recruiting ➔ Completed

Trial completion • Alzheimer's Disease • CNS Disorders

Clinical Development of Passive Tau-Based Immunotherapeutics for Treating Primary and Secondary Tauopathies. (PubMed, Expert Opin Investig Drugs) - "At present, 14 anti-tau antibodies have entered clinical trials, and 9 of them are still in clinical testing for progressive supranuclear palsy syndrome and AD (semorinemab, bepranemab, E2814, JNJ-63733657, Lu AF87908, APNmAb005, MK-2214, PNT00, and PRX005). The most advanced anti-tau monoclonal antibody for treating AD is semorinemab, while bepranemab is the only anti-tau monoclonal antibody still in clinical testing for treating progressive supranuclear palsy syndrome. Further evidence on passive immunotherapeutics for treating primary and secondary tauopathies will come from ongoing Phase I/II trials."

Journal • Review • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Frontotemporal Lobar Degeneration • Movement Disorders • Progressive Supranuclear Palsy

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease (clinicaltrials.gov) - P1 | N=86 | Active, not recruiting | Sponsor: H. Lundbeck A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Alzheimer's Disease • CNS Disorders

A Quantitative LC-MS/MS Method for Distinguishing the Tau Protein Forms Phosphorylated and Nonphosphorylated at Serine-396. (PubMed, J Am Soc Mass Spectrom) - "In addition, the method was applied for rTg4510 mice where a clear dose dependent decrease in pS396-tau was observed in CSF following intravenous administration of a monoclonal antibody (Lu AF87908, hC10.2) targeting the tau epitope containing pS396. Finally, a formal validation of the method was conducted. In conclusion, this sensitive LC-MS/MS-based method for measurement of pS396-tau in CSF allows for quantitative translational biomarker applications for tauopathies including investigations of potential drug induced effects."

Journal • Alzheimer's Disease • CNS Disorders • Cognitive Disorders

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: H. Lundbeck A/S | Trial completion date: Nov 2022 ➔ Jun 2023 | Trial primary completion date: Nov 2022 ➔ Jun 2023

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease (clinicaltrials.gov) - P1 | N=88 | Recruiting | Sponsor: H. Lundbeck A/S | Trial completion date: Jul 2022 ➔ Nov 2022 | Trial primary completion date: Jul 2022 ➔ Nov 2022

Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders

Study With Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease (clinicaltrials.gov) - P1; N=96; Recruiting; Sponsor: H. Lundbeck A/S; Trial completion date: May 2021 ➔ Jul 2022; Trial primary completion date: May 2021 ➔ Jul 2022

Clinical • Trial completion date • Trial primary completion date • Alzheimer's Disease • CNS Disorders

Study With Lu AF87908 in Healthy Subjects and Patients With Alzheimer's Disease (clinicaltrials.gov) - P1; N=96; Recruiting; Sponsor: H. Lundbeck A/S

Clinical • New P1 trial